NMRA Stock Analysis: Buy, Sell, or Hold?
NMRA - Neumora Therapeutics, Inc. Common Stock
$1.63
-0.12 (-6.86%)
▼
5d:
-11.89%
30d:
-30.04%
90d:
-46.03%
WAIT
LOW Confidence
Analysis Updated: Jun 5, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When NMRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NMRA is down 11.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NMRA is down 11.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NMRA is currently trading at $1.63, which is considered oversold relative to its 30-day fair value range of $1.72 to $2.20.
Technical Outlook: Technically, NMRA is in a downtrend. The price is currently testing key support at $1.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.91 (+446.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NMRA is in a downtrend. The price is currently testing key support at $1.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.91 (+446.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.72 -
$2.20
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 446.5% below Wall St target ($8.91)
- WARNING: Recommendation downgraded due to -11.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.72 -
$2.20
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.66
Resistance Level
$1.98
Current Trend
Downtrend
Technical data as of
Jun 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.83
Wall Street Target
$8.91
(+446.5%)
Share & Embed Analysis
Last updated: June 06, 2026 8:10 AM ET
Data refreshes hourly during market hours. Next update: 9:10 AM
Data refreshes hourly during market hours. Next update: 9:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NMRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Daljit Singh Aurora
SELL
6165 shares
2026-02-17
Joshua Pinto
SELL
5967 shares
2026-02-17
Michael Lee Milligan
SELL
1436 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 61 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$183 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$126 | 58 HOLD |